Grants and Contributions:
Title:
POC of AI-Nano-antibody design and Validation for AD
Agreement Number:
1034082
Agreement Value:
$75,000.00
Agreement Date:
Sep 1, 2025 - Jan 2, 2026
Description:
Nanil Therapeutics is validating its proprietary BioDesign-AI platform through experimental assessment of AI-generated nanobody sequences targeting tau, a key protein in Alzheimer’s disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T2L 1Y8
Reference Number:
172-2025-2026-Q2-1034082
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
720648021
Recipient Type:
For-profit organization
Recipient's Operating Name:
Nanil Therapeutics Inc.
Recipient's Legal Name:
Nanil Therapeutics Inc
Federal Riding Name:
Calgary Confederation
Federal Riding Number:
48005
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254